Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleReviewsR

Genetic and Epigenetic Aspects of Breast Cancer Progression and Therapy

SHANNON BYLER, SARAH GOLDGAR, SARAH HEERBOTH, MEGHAN LEARY, GENEVIEVE HOUSMAN, KIMBERLY MOULTON and SIBAJI SARKAR
Anticancer Research March 2014, 34 (3) 1071-1077;
SHANNON BYLER
Cancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SARAH GOLDGAR
Cancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SARAH HEERBOTH
Cancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MEGHAN LEARY
Cancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GENEVIEVE HOUSMAN
Cancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIMBERLY MOULTON
Cancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SIBAJI SARKAR
Cancer Center, Department of Medicine, Boston University School of Medicine, Boston, MA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ss1{at}bu.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Although breast cancer is a heterogeneous disease that is challenging to characterize and treat, the recent explosion of genetic and epigenetic research may help improve these endeavors. In the present review, we use genetic diversity to characterize and classify different types of breast cancer. We also discuss genetic and epigenetic changes that are involved in the development of different breast cancer types and examine how these changes affect prognosis. It appears that while a combination of mutations and copy number changes determine the type of breast cancer, epigenetic alterations may be the primary initiators of cancer development. Understanding these critical biomarkers and molecular changes will advance our ability to effectively treat breast cancer. Next, we examine potential drug therapies directed at epigenetic changes, as such epigenetic drug treatments may prove useful for treating patient-specific tumors, breast cancer progenitor cells, and drug-resistant cells. Lastly, we discuss on mechanisms of carcinogenesis, including a novel hypothesis outlining the role of epigenetics in the development of cancer progenitor cells and metastasis. Overall, breast cancer subtypes may have a similar epigenetic signal that promotes cancer development, and treatment may be most effective if both epigenetic and genetic differences are targeted.

  • Breast cancer
  • cancer
  • mutation
  • gene copy number
  • epigenetics
  • histone modification
  • histone deacetylase inhibitors
  • methylation
  • de-methylation
  • oncogene
  • tumor suppressor genes
  • metastasis
  • cancer progenitor cells
  • breast cancer progression
  • epithelial-mesenchymal transition (EMT)
  • therapeutics
  • combination therapy
  • drug resistance
  • review
  • Received December 20, 2013.
  • Revision received January 13, 2014.
  • Accepted January 14, 2014.
  • Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
View Full Text
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 34, Issue 3
March 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Genetic and Epigenetic Aspects of Breast Cancer Progression and Therapy
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
18 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Genetic and Epigenetic Aspects of Breast Cancer Progression and Therapy
SHANNON BYLER, SARAH GOLDGAR, SARAH HEERBOTH, MEGHAN LEARY, GENEVIEVE HOUSMAN, KIMBERLY MOULTON, SIBAJI SARKAR
Anticancer Research Mar 2014, 34 (3) 1071-1077;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Genetic and Epigenetic Aspects of Breast Cancer Progression and Therapy
SHANNON BYLER, SARAH GOLDGAR, SARAH HEERBOTH, MEGHAN LEARY, GENEVIEVE HOUSMAN, KIMBERLY MOULTON, SIBAJI SARKAR
Anticancer Research Mar 2014, 34 (3) 1071-1077;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Somatic Mutations
    • Copy Number Aberrations
    • Somatic Mutations, Copy Number Aberrations, and Protein Expression
    • Epigenetic Changes
    • Epigenetic Drug Treatment
    • Carcinogenesis Model
    • Further Studies
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Phenotypic and Functional Characterization of Oncohistone Mutations in Breast Cancers
  • A Divide-and-Conquer Approach to Large-Scale Evolutionary Analysis of Single-Cell DNA Data
  • Building a genetic and epigenetic predictive model of breast cancer intrinsic subtypes using large-scale data and hierarchical structure learning
  • Identifying Proteasome 26S Subunit, ATPase (PSMC) Family Genes as the Prognostic Indicators and Therapeutic Targets in Lung Adenocarcinoma
  • Cancer Progenitor Cells: The Result of an Epigenetic Event?
  • Azacytidine-induced Chemosensitivity to Doxorubicin in Human Breast Cancer MCF7 Cells
  • The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells
  • Botanicals and Their Bioactive Phytochemicals for Womens Health
  • Google Scholar

More in this TOC Section

  • Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10
  • Proteolytic Enzyme Therapy in Complementary Oncology: A Systematic Review
  • Multimodal Treatment of Primary Advanced Ovarian Cancer
Show more Reviews

Keywords

  • Breast cancer
  • cancer
  • mutation
  • gene copy number
  • epigenetics
  • histone modification
  • histone deacetylase inhibitors
  • methylation
  • de-methylation
  • oncogene
  • tumor suppressor genes
  • metastasis
  • cancer progenitor cells
  • breast cancer progression
  • epithelial-mesenchymal transition (EMT)
  • therapeutics
  • combination therapy
  • drug resistance
  • review
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire